DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma.

DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma.

BACKGROUND: Treatment options for wild-type BRAF melanoma patients remain limited. Selumetinib, a MEK 1/2 inhibitor, suppresses pERK levels independent of BRAF and NRAS mutation status, and combination with docetaxel has demonstrated synergy in xenograft models. The aim of this study was to assess t...

Mô tả đầy đủ

Chi tiết về thư mục
Những tác giả chính:	Gupta, A, Love, S, Schuh, A, Shanyinde, M, Larkin, J, Plummer, R, Nathan, P, Danson, S, Ottensmeier, C, Lorigan, P, Collins, L, Wise, A, Asher, R, Lisle, R, Middleton, MR
Định dạng:	Journal article
Ngôn ngữ:	English
Được phát hành:	Oxford University Press 2014

Những quyển sách tương tự

DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma
Bằng: Gupta, A, et al.
Được phát hành: (2013)

Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma
Bằng: Gupta, A, et al.
Được phát hành: (2020)

Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: A phase 2 double-blind randomised study
Bằng: Robert, C, et al.
Được phát hành: (2013)

Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
Bằng: Robert, C, et al.
Được phát hành: (2013)

Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.
Bằng: Kirkwood, J, et al.
Được phát hành: (2012)

Improved survival with MEK inhibition in BRAF-mutated melanoma.
Bằng: Flaherty, K, et al.
Được phát hành: (2012)

Phase I trial of the MEK inhibitor selumetinib in combination with thoracic radiotherapy in non-small cell lung cancer
Bằng: K. Haslett, et al.
Được phát hành: (2021-05-01)

The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment
Bằng: Edmund Poon, et al.
Được phát hành: (2017-08-01)

Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma
Bằng: Jessie Villanueva, et al.
Được phát hành: (2013-09-01)

Immunological effects of BRAF+MEK inhibition
Bằng: Paolo A. Ascierto, et al.
Được phát hành: (2018-09-01)

Treatment with BRAF/MEK: inhibitors in mutant BRAF V600E papillary craniopharyngioma
Bằng: Eva Marie Erfurth, et al.
Được phát hành: (2024-12-01)

Exploring New Drug Repurposing Opportunities for MEK Inhibitors in RASopathies: A Comprehensive Review of Safety, Efficacy, and Future Perspectives of Trametinib and Selumetinib
Bằng: Andrea Gazzin, et al.
Được phát hành: (2024-06-01)

Identification of the Major Degradation Pathways of Selumetinib
Bằng: Tahar Sif eddine Bouchema, et al.
Được phát hành: (2022-11-01)

A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors
Bằng: Pacey, S, et al.
Được phát hành: (2016)

Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy.
Bằng: Anne L Estep, et al.
Được phát hành: (2007-12-01)

Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma
Bằng: Sara Bjursten, et al.
Được phát hành: (2019-11-01)

Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma
Bằng: Sarah J. Welsh, et al.
Được phát hành: (2015-03-01)

Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma
Bằng: Blessie Elizabeth Nelson, et al.
Được phát hành: (2023-05-01)

Effect of food on capsule and granule formulations of selumetinib
Bằng: Sarit Cohen‐Rabbie, et al.
Được phát hành: (2022-04-01)

Neuroprotective effect of selumetinib on acrolein-induced neurotoxicity
Bằng: Hui-Ju Huang, et al.
Được phát hành: (2021-06-01)

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors
Bằng: Leijen, S, et al.
Được phát hành: (2011)

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors.
Bằng: Leijen, S, et al.
Được phát hành: (2011)

Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma
Bằng: Bengt Tholander, et al.
Được phát hành: (2020-10-01)

BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation
Bằng: Ken Saijo, et al.
Được phát hành: (2022-08-01)

Autoimmunity associated with Erdheim-Chester disease improves with BRAF/MEK inhibitors
Bằng: Anaïs Roeser, et al.
Được phát hành: (2019-11-01)

Genetics-guided therapy in neuroendocrine carcinoma: response to BRAF- and MEK-inhibitors
Bằng: Lovisa Falkman, et al.
Được phát hành: (2024-04-01)

Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors
Bằng: Clare Judith Stones, et al.
Được phát hành: (2013-05-01)

Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management
Bằng: Jan Leipe, et al.
Được phát hành: (2019-06-01)

Case report: Metastatic BRAF V600E–mutated adult Wilms’ tumor with robust response to BRAF/MEK inhibitor therapy
Bằng: Matthew R. Kroll, et al.
Được phát hành: (2024-07-01)

Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy
Bằng: Shivshankari Rajkumar, et al.
Được phát hành: (2022-04-01)

Efficacy of BRAF/MEK-inhibitor therapy for epithelioid glioblastoma with a novel BRAFV600 mutation
Bằng: J. Steininger, et al.
Được phát hành: (2024-08-01)

REPEATED USE OF BRAF AND MEK INHIBITORS IN METASTATIC MELANOMA PATIENTS AFTER PROFRESSION ON BRAF AND МЕК INHIBITORS. LITERATURE REVIEW AND CLINICAL OBSERVATION
Bằng: I. V. Samoylenko, et al.
Được phát hành: (2017-11-01)

Exceptional response to rechallenge of BRAF/MEK inhibitors in patients with primary acquired resistance to targeted therapy
Bằng: B. Ziółkowska, et al.
Được phát hành: (2024-01-01)

BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association
Bằng: Michael J. Vido, et al.
Được phát hành: (2018-11-01)

Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy
Bằng: Zeynep Eroglu, et al.
Được phát hành: (2016-01-01)

Multiple epidermotropic melanoma metastases developing during BRAF and MEK inhibitor therapy
Bằng: Raphael Reinhard, MD, et al.
Được phát hành: (2018-03-01)

A case of malignant transformation of a serous borderline ovarian tumor effectively treated with BRAF/MEK inhibitor combination
Bằng: Manrose Singh, et al.
Được phát hành: (2024-08-01)

Novel therapy: Combined BRAF and MEK inhibitors for locally advanced BRAF V600L–Positive mucosal melanoma in hypopharynx
Bằng: Sivakamavalli Jeyachandran
Được phát hành: (2024-06-01)

High BRAF V600 Mutation Level Associated with Worse Outcome in Metastatic Melanoma Patients Receiving BRAF and MEK Inhibitors
Bằng: Ariane Fizazi, et al.
Được phát hành: (2024-11-01)

ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration‐resistant prostate cancer patients: A phase Ib study
Bằng: Marit A. C. Vermunt, et al.
Được phát hành: (2021-08-01)